AN2728 meets psoriasis endpoint

Anacor Pharmaceuticals Inc. (Palo Alto, Calif.) said topical 2% AN2728 twice daily met the primary endpoint in a Phase IIb trial to treat psoriasis. AN2728 produced a significantly higher proportion o...